JP Morgan raises the Price Target to $63 from $61 after Humana HUM posted Q4 EPS of “$0.63 vs our/consensus $0.69/0.78.”
The report notes, “much like others this season so far, the report benefited from moderate med utilization offset by a heavy dose of cleanup/one-time items (about $1/share) which held down the reported EPS. With this follow-up note to our detailed report yesterday, we are updating our '11 and '12 EPS estimates, raising each by $0.20, to $6.20 and $6.00 respectively.”
JP Morgan raises the Price Target to $63 and maintains its Neutral rating.
Humana is currently trading unchanged in the premarket from Tuesday's close of $58.31.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in